EA026810B1 - Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством - Google Patents

Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством Download PDF

Info

Publication number
EA026810B1
EA026810B1 EA201100621A EA201100621A EA026810B1 EA 026810 B1 EA026810 B1 EA 026810B1 EA 201100621 A EA201100621 A EA 201100621A EA 201100621 A EA201100621 A EA 201100621A EA 026810 B1 EA026810 B1 EA 026810B1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
diabetes
sulfonylurea
dpp
metformin
Prior art date
Application number
EA201100621A
Other languages
English (en)
Russian (ru)
Other versions
EA201100621A1 (ru
Inventor
Эва Ульрике Грэфе-Моди
Томас Клайн
Михаэль Марк
Ханс-Юрген Вёрле
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA026810(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201100621A1 publication Critical patent/EA201100621A1/ru
Publication of EA026810B1 publication Critical patent/EA026810B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
EA201100621A 2008-10-16 2009-10-15 Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством EA026810B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10591908P 2008-10-16 2008-10-16
EP08166829 2008-10-16
EP09167304 2009-08-05
PCT/EP2009/063511 WO2010043688A1 (en) 2008-10-16 2009-10-15 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Publications (2)

Publication Number Publication Date
EA201100621A1 EA201100621A1 (ru) 2011-12-30
EA026810B1 true EA026810B1 (ru) 2017-05-31

Family

ID=41426834

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100621A EA026810B1 (ru) 2008-10-16 2009-10-15 Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством

Country Status (20)

Country Link
US (3) US20110275561A1 (enExample)
EP (2) EP3150204A3 (enExample)
JP (6) JP2012505859A (enExample)
KR (6) KR20170053742A (enExample)
CN (3) CN102186466A (enExample)
AR (1) AR073876A1 (enExample)
AU (1) AU2009305419B2 (enExample)
CA (1) CA2738367C (enExample)
CO (1) CO6361917A2 (enExample)
EA (1) EA026810B1 (enExample)
EC (1) ECSP11010971A (enExample)
IL (1) IL211370A0 (enExample)
MA (1) MA32872B1 (enExample)
MX (4) MX2011003774A (enExample)
NZ (2) NZ605207A (enExample)
PE (1) PE20110396A1 (enExample)
TN (1) TN2011000176A1 (enExample)
TW (1) TWI520738B (enExample)
UY (1) UY32177A (enExample)
WO (1) WO2010043688A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) * 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
NZ619520A (en) * 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2427195B1 (en) * 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP5826830B2 (ja) * 2010-05-05 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピオグリタゾンとリナグリプチンを含む医薬製剤
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
AU2016202261B2 (en) * 2010-11-15 2017-11-30 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
JP6374862B2 (ja) * 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
KR20210099201A (ko) * 2013-03-15 2021-08-11 베링거 인겔하임 인터내셔날 게엠베하 심장보호 및 신장보호 항당뇨병 치료요법에서의 리나글립틴의 사용
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
TWI682931B (zh) * 2015-05-29 2020-01-21 大陸商江蘇天士力帝益藥業有限公司 黃嘌呤衍生物、其藥物組成物、其製劑以及其用途
JP7042755B2 (ja) 2016-06-05 2022-03-28 バーグ エルエルシー 患者層別化及び潜在的バイオマーカー同定のためのシステム及び方法
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018468A2 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel
WO2004050658A1 (de) * 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
WO2005085246A1 (de) * 2004-02-18 2005-09-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007071738A1 (en) * 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as dpp-iv inhibitors
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
WO2009022008A1 (en) * 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a pyrazole-o-glucoside derivative
WO2009022007A1 (en) * 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
DE10238470A1 (de) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
PT1558220E (pt) * 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
EP1671649B1 (en) * 2003-10-03 2011-11-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
JP2005126430A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd 糖尿病治療剤
EP1782832A4 (en) * 2004-08-26 2009-08-26 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF DIABETES
US8338450B2 (en) * 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
BRPI0920699A2 (pt) * 2008-10-16 2020-09-01 Boehringer Ingelheim International Gmbh uso de um inibidor de dpp-4 no tratamento de diabetes em pacientes com controle insuficiente da glicemia apesar de terapia com um fármaco antidiabético oral ou não-oral
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
NZ599298A (en) * 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018468A2 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel
WO2004050658A1 (de) * 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
WO2005085246A1 (de) * 2004-02-18 2005-09-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007071738A1 (en) * 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as dpp-iv inhibitors
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
WO2009022008A1 (en) * 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a pyrazole-o-glucoside derivative
WO2009022007A1 (en) * 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ECKHARDT, M. ; HAUEL, N. ; HIMMELSBACH, F. ; LANGKOPF, E. ; NAR, H. ; MARK, M. ; TADAYYON, M. ; THOMAS, L. ; GUTH, B. ; LOTZ, R.: "3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 11, 1 June 2008 (2008-06-01), AMSTERDAM, NL, pages 3158 - 3162, XP022711188, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2008.04.075 *
GRAEFE-MODY, ET AL.: "The novel DPP-4 inhibitor BI1356...", DIABETES, 1 January 2008 (2008-01-01), pages 1, XP002561421, Retrieved from the Internet <URL:http://professional.diabetes.org/Content/Posters/2008/p553-P.pdf> [retrieved on 20091221] *
PEI Z: "From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 11, no. 4, 1 July 2008 (2008-07-01), GB, pages 512 - 532, XP009110228, ISSN: 1367-6733 *
WANG Y; SERRADELL N; ROSA E; CASTANER R: "BI-1356. Dipeptidyl-peptidase IV inhibitor, antidiabetic agent", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 33, no. 6, 1 June 2008 (2008-06-01), ES, pages 473 - 477, XP009110227, ISSN: 0377-8282, DOI: 10.1358/dof.2008.033.06.1215244 *

Also Published As

Publication number Publication date
KR102427380B9 (ko) 2025-11-13
CA2738367A1 (en) 2010-04-22
KR20220110860A (ko) 2022-08-09
CN108042543A (zh) 2018-05-18
JP2025029032A (ja) 2025-03-05
TW201021802A (en) 2010-06-16
CN109700814A (zh) 2019-05-03
KR20200013100A (ko) 2020-02-05
AU2009305419A1 (en) 2010-04-22
ECSP11010971A (es) 2011-05-31
KR102427380B1 (ko) 2022-08-01
TWI520738B (zh) 2016-02-11
PE20110396A1 (es) 2011-07-17
JP6811203B2 (ja) 2021-01-13
JP6262023B2 (ja) 2018-01-17
US20160058769A1 (en) 2016-03-03
AR073876A1 (es) 2010-12-09
CN102186466A (zh) 2011-09-14
WO2010043688A1 (en) 2010-04-22
KR20110066936A (ko) 2011-06-17
MX2011003774A (es) 2011-05-23
KR20240046643A (ko) 2024-04-09
JP2012505859A (ja) 2012-03-08
JP2018131450A (ja) 2018-08-23
JP2016164161A (ja) 2016-09-08
JP2022125360A (ja) 2022-08-26
CA2738367C (en) 2017-04-04
AU2009305419B2 (en) 2015-08-27
KR20180035948A (ko) 2018-04-06
EP3150204A2 (en) 2017-04-05
EP3150204A3 (en) 2017-06-14
UY32177A (es) 2010-05-31
MX2022001797A (es) 2022-03-22
TN2011000176A1 (en) 2012-12-17
EP2349240A1 (en) 2011-08-03
NZ591996A (en) 2013-03-28
MX2020009811A (es) 2020-10-14
US20170368068A1 (en) 2017-12-28
NZ605207A (en) 2014-07-25
KR20170053742A (ko) 2017-05-16
JP2014129393A (ja) 2014-07-10
EA201100621A1 (ru) 2011-12-30
MA32872B1 (fr) 2011-12-01
CO6361917A2 (es) 2012-01-20
MX375132B (es) 2025-03-06
US20110275561A1 (en) 2011-11-10
IL211370A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
JP6811203B2 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP6290627B2 (ja) メトホルミン治療に不適切な患者における糖尿病の治療
JP6189374B2 (ja) 糖尿病療法
JP5906086B2 (ja) Ｆａｂ関連疾患の治療に用いるためのプリン誘導体
JP2012505859A6 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2019055984A (ja) メトホルミン治療に不適切な患者における糖尿病の治療
JP7174020B2 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
US11911388B2 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US20240148737A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP6480887B2 (ja) メトホルミン治療に不適切な患者における糖尿病の治療
EA044961B1 (ru) Лечение диабета
EA041228B1 (ru) Лечение диабета

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM